People · Operator
Named in public records as an officer, director or promoter · active 2007–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tetra Discovery Partners, Inc. | — | Biotechnology | Series B | $40.5M | $1.4B | 2016 |
| Tolera Therapeutics Inc | — | Biotechnology | Series A | $13.9M | $9.0M | 2010 |
| Nephrx Corp | — | Biotechnology | Series A | $6.2M | $224.8M | 2007 |
Douglas Morton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Morton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Donald Parfet | 3 | 5 |
| Patrick Morand | 1 | 5 |
| Ashleigh Palmer | 1 | 4 |
| Paul D'Amato | 1 | 4 |
| Mark Olesnavage | 1 | 4 |
| Suzette Dutch | 1 | 3 |
| THOMAS COX | 1 | 2 |
| JAMES KOZIARZ | 1 | 2 |
| Lance Stewart | 1 | 2 |
| John Puisis | 1 | 2 |
| Charles Hall | 1 | 2 |
| William McGinnis | 1 | 1 |
| Joseph Collard | 1 | 1 |
| Phillip Long | 1 | 1 |
| Elizabeth Long | 1 | 1 |
| James Herrmann | 1 | 1 |
| Mark Gurney | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.